Literature DB >> 25812827

A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.

Meng Wei1, Meirong Huang, Shubao Chen, Guoying Huang, Min Huang, Dingzhong Qiu, Zhongzhen Guo, Jingjing Jiang, Xiaoxun Zhou, Qing Yu, Ying Guo, Lijun Fu, Wei Gao, Feng Li.   

Abstract

To investigate the relationship between the risk factors associated with intravenous immunoglobulin (IVIG) non-response and the incidence of coronary artery lesions (CAL) in patients with Kawasaki disease (KD). A retrospective study was performed on clinical records of 1953 KD patients who were admitted to hospitals in Shanghai, China, between 1998 and 2007. Related clinical and laboratory findings were studied using univariate and multivariate statistical analyses. Of the 1953 KD patients, 133 (6.8 %) were unresponsive to IVIG therapy, and 356 (18.6 %) developed CAL. The incidence of CAL in the non-responsive IVIG group was significantly different from that in the responsive IVIG group (31.3 vs. 17.6 %). The incidence of IVIG non-response was significantly lower in the patients who received sufficient doses of IVIG than in the patients who received insufficient doses (5.2 vs. 18.1 %). A logistic regression analysis of 1295 patients who received sufficient IVIG doses indicated that cervical lymph node enlargement, CAL, erythrocyte sedimentation rate (ESR) ≥75 mm/h, and platelet count (PLT) ≥530 × 10(9)/L were independent risk factors of IVIG non-response. IVIG non-responders are prone to develop CAL. Initiation of therapy with sufficient IVIG doses at the early stage of the disease is crucial for preventing IVIG non-response. Lymph node enlargement, ESR ≥75 mm/h, and PLT count ≥530 × 10(9)/L are independent risk factors for predicting non-response to sufficient IVIG doses. For patients with the tendency of being unresponsive to IVIG therapy, treatment using sufficient IVIG doses combined with hormones or immunosuppressive agents should be considered to reduce the incidence of IVIG non-response and CAL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25812827     DOI: 10.1007/s00246-015-1138-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  7 in total

1.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Authors:  M Fukunishi; M Kikkawa; K Hamana; T Onodera; K Matsuzaki; Y Matsumoto; J Hara
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

2.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease.

Authors:  C A Wallace; J W French; S J Kahn; D D Sherry
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

3.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease.

Authors: 
Journal:  Pediatr Int       Date:  2005-12       Impact factor: 1.524

4.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

5.  Increased percentages of tumor necrosis factor-alpha+/interferon-gamma+ T [corrected] lymphocytes and calprotectin+/tumor necrosis factor-alpha+ monocytes in patients with acute Kawasaki disease.

Authors:  G Guggino; R Cimaz; S Accomando; I Pagnini; G Simonini; D Di Liberto; M De Martino; F Dieli; G Sireci
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Jan-Mar       Impact factor: 3.219

6.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Circulation       Date:  2004-10-26       Impact factor: 29.690

7.  Immunoglobulin failure and retreatment in Kawasaki disease.

Authors:  K Durongpisitkul; J Soongswang; D Laohaprasitiporn; A Nana; C Prachuabmoh; C Kangkagate
Journal:  Pediatr Cardiol       Date:  2002-12-04       Impact factor: 1.655

  7 in total
  9 in total

Review 1.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

2.  Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.

Authors:  Li-Jun Xue; Rong Wu; Gui-Lian Du; Yan Xu; Kang-Yan Yuan; Zhi-Chun Feng; Yu-Lin Pan; Guang-Yu Hu
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 3.  Kawasaki Disease: Pathology, Risks, and Management.

Authors:  Mitsuru Seki; Takaomi Minami
Journal:  Vasc Health Risk Manag       Date:  2022-06-10

4.  Combined IFN-β and PLT Detection Can Identify Kawasaki Disease Efficiently.

Authors:  Kan Huijuan; Dong Yaping; Wang Bo; Hou Miao; Qian Guanghui; Yan Wenhua
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

5.  Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment.

Authors:  Euri Seo; Jeong Jin Yu; Hyun Ok Jun; Eun Jung Shin; Jae Suk Baek; Young-Hwue Kim; Jae-Kon Ko
Journal:  Korean J Pediatr       Date:  2016-10-17

6.  Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea.

Authors:  Hong-Ryang Kil; Jae-Won Yu; Sung-Churl Lee; Jung-Woo Rhim; Kyung-Yil Lee
Journal:  Pediatr Rheumatol Online J       Date:  2017-08-07       Impact factor: 3.054

7.  Homozygous of MRP4 Gene rs1751034 C Allele Is Related to Increased Risk of Intravenous Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Yanfei Wang; Yufen Xu; Ping Huang; Di Che; Zhouping Wang; Xijing Huang; Xiaofei Xie; Wei Li; Li Zhang; Xiaoqiong Gu
Journal:  Front Genet       Date:  2021-03-15       Impact factor: 4.599

8.  Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China.

Authors:  Hongbiao Huang; Jiaqi Jiang; Xiaosong Shi; Jie Qin; Jinfeng Dong; Lei Xu; Chengcheng Huang; Ying Liu; Yiming Zheng; Miao Hou; Qin Shen; Bihe Zeng; Guanghui Qian; Fang Yang; Haitao Lv
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

9.  FCN1 (M-ficolin), which directly associates with immunoglobulin G1, is a molecular target of intravenous immunoglobulin therapy for Kawasaki disease.

Authors:  Daisuke Okuzaki; Kaori Ota; Shin-Ichi Takatsuki; Yukari Akiyoshi; Kazuyuki Naoi; Norikazu Yabuta; Tsutomu Saji; Hiroshi Nojima
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.